Crystalline forms of Fentanyl Alkaloid
The present invention provides crystalline forms of fentanyl alkaloid and methods for preparing crystalline forms of fentanyl alkaloid.
1 . A crystalline form of fentanyl alkaloid, N-[1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide, the crystalline form being Form II.
2 . The crystalline form of claim 1 , wherein Form II exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 8.9, about 17.9, about 19.4, and about 21.4.
3 . The crystalline form of claim 1 , wherein Form II exhibits an endothermic transition with an onset of about 70°-73° C. as measured by differential scanning calorimetry.
4 . The crystalline form of claim 1 , wherein Form II comprises no more than about 5% by weight of another form of fentanyl alkaloid.
5 . A pharmaceutical composition, the composition comprising crystalline Form II of fentanyl alkaloid, N-[1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide, and at least one pharmaceutically acceptable excipient.
6 . The pharmaceutical composition of claim 5 , wherein crystalline Form II exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 8.9, about 17.9, about 19.4, and about 21.4, and an endothermic transition with an onset of about 70°-73° C. as measured by differential scanning calorimetry.
7 . The pharmaceutical composition of claim 5 , further comprising another crystalline or amorphous form of fentanyl alkaloid.
8 . The pharmaceutical composition of claim 5 , further comprising crystalline Form I of fentanyl alkaloid.
9 . The pharmaceutical composition of claim 8 , wherein Form I exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 7.4, about 9.6, about 15.5, 18.9 and about 22.1, and an endothermic transition with an onset of about 83°-85° C. as measured by differential scanning calorimetry.
10 . A process for preparing a substantially pure crystalline form of fentanyl alkaloid, N-[1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide, the process comprising:
a) contacting fentanyl alkaloid with a solvent to form a saturated or near saturated solution; and
b) evaporating the solvent in the solution to form a mass of crystals of the substantially pure crystalline form.
11 . The process of claim 10 , wherein the solvent is slowly evaporated in an inert atmosphere.
12 . The process of claim 10 , further comprising the step of collecting the crystals of the substantially pure crystalline form.
13 . The process of claim 12 , further comprising the step of drying the crystals of the substantially pure crystalline form.
14 . The process of claim 10 , wherein the solvent is selected from the group consisting of a protic solvent selected from the group consisting of methanol, ethanol, isopropanol, n-propanol, isobutanol, n-butanol, t-butanol, water, formic acid, and acetic acid; an aprotic solvent selected from the group consisting of acetone, acetonitrile, dichloromethane, and tetrahydrofuran; and combinations thereof.
15 . The process of claim 10 , wherein the solvent is a mixture of methanol and water, and the crystalline form is Form I, which exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 7.4, about 9.6, about 15.5, 18.9, and about 22.1, and an endothermic transition with an onset of about 83°-85° C. as measured by differential scanning calorimetry.
16 . The process of claim 10 , wherein the solvent is a mixture of ethanol and water, and the crystalline form is Form I, which exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 8.9, about 17.9, about 19.4, and about 21.4, and an endothermic transition with an onset of about 83°-85° C. as measured by differential scanning calorimetry.
17 . The process of claim 10 , wherein the solvent is a mixture of isopropanol and water, and the crystalline form is Form II, which exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at 8.9, about 17.9, about 19.4, and about 21.4, and an endothermic transition with an onset of about 70°-73° C. as measured by differential scanning calorimetry.
18 . A process for converting a crystalline Form I of fentanyl alkaloid into a crystalline Form II of fentanyl alkaloid, the process comprising:
a) melting the crystalline Form I of fentanyl alkaloid;
b) cooling the fentanyl alkaloid from step a); and
c) heating the fentanyl alkaloid from step b) to form the crystalline Form II of fentanyl alkaloid.
19 . The process of claim 18 , wherein step a) is conducted at a temperature of about 86° C. to about 90° C.
20 . The process of claim 19 , wherein step b) is conducted at a temperature of less than about −25° C.
21 . The process of claim 20 , wherein step c) is conducted at a temperature of about 30° C. to about 50° C.
22 . The process of claim 18 , wherein the crystalline Form I exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 7.4, about 9.6, about 15.5, 18.9, and about 22.1, and an endothermic transition with an onset of about 83°-85° C. as measured by differential scanning calorimetry.
23 . The process of claim 18 , wherein the crystalline Form II exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 8.9, about 17.9, about 19.4, and about 21.4, and an endothermic transition with an onset of about 70°-73° C. as measured by differential scanning calorimetry.